Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir

Sofosbuvir 400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)

Trial Locations (19)

Unknown

Akita

Chiba

Chiyoda-ku

Gifu

Ichikawa

Itabashi-ku

Izunokuni

Kita-ku

Kurashiki

Kurume

Matsumoto

Musashino

Nishinomiya

Ōgaki

Ōmura

Sapporo

Shinjuku-ku

Suita

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY